Is Moderna (MRNA) a Buy Right Now?
A plain-English read on Moderna stock — what the chart and the numbers are saying today, with no jargon and no hype.
What this means, in plain English
Moderna is currently trading at $59.17. We look at the 200-day average, which is the average price over the last 200 days, currently at $46.33. Because the price is above this level, the long-term trend is considered up. The stock rose 9.86% today, showing recent momentum.
The RSI, or Relative Strength Index—a gauge of whether a stock has climbed too far, too fast—is at 51.9. This suggests the stock is in a neutral zone, neither overbought nor oversold. With support at $52.66 and resistance at $62.43, the price is currently moving within a defined range.
Should you buy Moderna stock?
Based on the data showing a positive trend, the verdict is a buy. This decision reflects the current price action relative to its long-term averages. Always remember that market conditions change, so keep your position size small.
Is MRNA a good stock for beginners?
Moderna is a large company, but it remains volatile, meaning the price can swing significantly in a short time. With a P/E ratio of -12.2, which measures the price relative to earnings, the company is currently not profitable. Beginners should be cautious with stocks that lack consistent earnings.
What's driving MRNA right now
The stock price of $59.17 remains comfortably above its 200-day average of $46.33.
The RSI of 51.9 indicates the stock is not currently overextended in either direction.
The recent support level of $52.66 provides a reference point for where buyers have stepped in previously.
The P/E ratio of -12.2 highlights that the company is not currently generating a profit.
What Moderna actually does
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Moderna by the numbers
Wall Street consensus on MRNA is Hold. That is the analyst community's view, shown for context — it is not our read and not a recommendation.
Who owns Moderna?
Institutions — pension funds, asset managers, index providers — hold 78.5% of MRNA, and the concentration matters: the largest single holder alone controls 11.44% of the company.
| Holder | Shares | % held |
|---|---|---|
| 45.67M | 11.44% | |
| 29.64M | 7.42% | |
| 22.87M | 5.73% |
Names withheld — plus 3 more records not shown.
See who owns itWhat Moderna insiders have been doing
Executives and directors must disclose their own trades in company stock. Of the last 6 disclosed transactions we hold for Moderna, 2 were sales and 0 were open-market purchases; the other 4 were awards, vesting or option exercises rather than a decision to buy or sell. Insiders sell for many ordinary reasons — scheduled plans, tax, diversification — so a sale is not by itself a signal.
| Insider | Date | Type | Shares | Value |
|---|---|---|---|---|
| 2026-07-15 | AWARD / VEST | 53.3K | $1.0M | |
| 2026-07-15 | SELL | 53.3K | $3.6M | |
| 2026-07-02 | AWARD / VEST | 1.5K | — |
Names withheld — plus 3 more records not shown.
See which insidersThe numbers behind the read
Who in Washington has been trading MRNA?
Members of Congress must disclose trades over $1,000 within 45 days under the STOCK Act. 4 disclosures name MRNA — filed by 2 separate members and worth $18K–$95K combined (filings report bands, never exact amounts). 0 purchase-side, 4 sale-side, most recently on 2021-07-22.
| Member | Date | Action | Amount filed |
|---|---|---|---|
| 2021-07-22 | SELL | $1,001 - $15,000 | |
| 2021-01-29 | SELL | $15,001 - $50,000 | |
| 2021-01-29 | SELL | $1,001 - $15,000 |
Names withheld — plus 1 more record not shown.
See which membersModerna is a buy because it is trading above its long-term trend line, showing technical strength despite the company's current lack of profitability.
Don't guess. Practice this trade first.
Buy it with virtual cash and watch how it plays out — before a dollar of your own is on the line.
Practice MRNA risk-free in your paper portfolioPaper trading, the AI Read & live indicators are inside a Money GPS membership — one price, the whole platform.
Beginner questions about MRNA
Should I buy MRNA stock?+
The data currently supports a buy rating because the price is trending above its 200-day average of $46.33.
Is MRNA a good long-term investment?+
It is difficult to label it a long-term investment while the company has a negative P/E ratio of -12.2.
Is MRNA a buy or a sell?+
Based on the current price of $59.17 sitting above the 200-day average, the technical data points to a buy.
Is MRNA overvalued?+
With a price of $59.17, it sits between the support of $52.66 and the resistance of $62.43, suggesting it is fairly valued within its current range.
Is MRNA a good stock for beginners?+
Beginners should be careful, as the stock has a wide 52-week range of $22.28 to $85.6 and is not currently profitable.
Important disclaimer
This page is for educational and informational purposes only and is not financial, investment, tax, or legal advice, nor a recommendation, offer, or solicitation to buy, sell, or hold Moderna (MRNA) or any other security. The Money GPS is not a registered investment adviser, broker-dealer, or financial planner, and no content here should be relied upon to make an investment decision.
The verdict, indicators, and commentary are generated automatically — in part using AI — from third-party market data (via Yahoo Finance) that may be delayed, incomplete, or inaccurate, and is provided “as is” without any warranty. Figures reflect the market as of 2026-08-07 and change constantly; the read above may already be out of date. A “Buy,” “Hold,” or “Be Careful” label is a simplified, rules-based signal for beginners — not a price target or a guarantee of any outcome.
All investing involves risk, including the possible loss of your entire principal. Past performance and historical patterns do not guarantee future results. Always do your own research and consult a licensed financial professional who knows your personal circumstances before investing. You are solely responsible for your own investment decisions. The Money GPS and its authors may hold positions in the securities discussed and accept no liability for any loss arising from the use of this information.